Corstasis Therapeutics Inc., a company in the early stages of developing treatments for fluid buildup linked to heart, kidney, and liver issues, has welcomed Dr. Amin M. Medjamia as their new Vice President of Medical Affairs. Dr. Medjamia has more than two decades of experience in biotech and medical devices. At Corstasis, he will be in charge of clinical strategy, scientific communication, and creating clinical algorithms through medical engagement as the company works on its main treatment, Enbumyst (bumetanide nasal spray).
Health Technology Insights: Pacific AI Expands Policy Suite for Global AI Compliance
Before coming to Corstasis, Dr. Medjamia worked at Abiomed, which is part of Johnson & Johnson’s MedTech division. There, he was in charge of generating global evidence for devices that support blood circulation. His work helped get regulatory approvals, reach payment goals in important markets like France and Japan, and manage big international studies.
Health Technology Insights: PatientFi Partners with Worth to Transform Healthcare Financing for Medical Procedures
Ben Esque, the CEO of Corstasis, is excited about Dr. Medjamia joining the team. He said Dr. Medjamia’s knowledge of heart conditions and strategies based on evidence will be key in developing new treatments that improve patient results and reduce healthcare expenses.
Dr. Medjamia is also enthusiastic about his new role, highlighting his dedication to expanding outpatient care options for patients suffering from fluid overload.
He expressed eagerness to contribute to Corstasis’ mission by helping develop therapies that improve the quality of life for patients dealing with these challenging conditions.
Health Technology Insights: Mark Mikhael Joins MAHA PAC Board for Patient Care Advocacy
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
